ClinicalTrials.Veeva

Menu
C

Clinica Universidad Catolica del Maule | Talca Centro - Oncology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
Doravirine
Islatravir
MK-7902
Docetaxel
Enzalutamide
ISL
Lenvatinib
DOR
Trastuzumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 15 total trials

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participa...

Enrolling
Metastasis
Castration-Resistant Prostatic Cancer
Drug: Rescue Medication
Drug: MK-5684

The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult participants with HIV-1 who had been previously treated with...

Active, not recruiting
HIV Infection
Drug: DOR/ISL

This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast ca...

Active, not recruiting
HER2 Positive Breast Cancer
Drug: Pertuzumab
Drug: Trastuzumab

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor,...

Enrolling
Non Small Cell Lung Cancer
Drug: Docetaxel
Biological: Telisotuzumab Vedotin

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alon...

Enrolling
Metastatic Castration-Resistant Prostate Cancer
Drug: PF-06821497
Drug: Placebo

The primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continu...

Active, not recruiting
HIV-1 Infection
Drug: BIC/FTC/TAF
Drug: DOR/ISL

This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of do...

Active, not recruiting
HIV-1 Infection
Drug: BIC/FTC/TAF
Drug: Placebo to DOR/ISL

The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared...

Active, not recruiting
Advanced/Metastatic Gastroesophageal Adenocarcinoma
Drug: 5-FU
Biological: Lenvatinib

This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus Androgen Deprivation Therapy (ADT) versus placebo plus enzalut...

Active, not recruiting
Metastatic Hormone-Sensitive Prostate Cancer
Drug: Androgen Deprivation Therapy (ADT)
Other: Placebo

Trial sponsors

Merck Sharp & Dohme (MSD) logo
AbbVie logo
Pfizer logo
S

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems